The clinical implications of platelet derived growth factor B, vascular endothelial growth factor and basic fibroblast growth factor in colorectal cancer

Journal of B.U.ON.

Volumn 16, Issue 2, 2011, Pages 274-276

  Ionescu, C ^a,b   Berindan Neagoe, Ioana ^b,c   Burz, C ^b   Balacescu, O ^c   Balacescu, L ^c,d   Tudoran, O ^c,d   Asztalos, R ^a   Irimie, A ^b,c  

^a Hospital 1   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^d BABE BOLYAI UNIVERSITY   (Romania)

Author keywords

bFGF; Colorectal cancer; PDGFb; qRT PCR; VEGF

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER STAGING; CARCINOGENESIS; CLINICAL ARTICLE; COLORECTAL CANCER; HUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

COLORECTAL NEOPLASMS; FIBROBLAST GROWTH FACTOR 2; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-SIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79960210558     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Adam R, Haller DG, Poston G, Raoul JL et al. Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer- an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. Ann Oncol 2010; 21: 1579-1585.
2. Ribatti D. Endogenous inhibitors of angiogenesis: A historical review. Leuk Res 2009; 33: 638-644.
3. Sato H, Usuda N, Kuroda M, Hashimoto S, Maruta M, Maeda K. Significance of serum concentrations of E-selectin and CA 19-9 in the prognosis of colorectal cancer. Jpn J Clin Oncol 2010; 40: 1073; 1080.
4. Uribarrena-Amezaga R, Ortego J, Fuentes J, Raventos N, Parra P, Uribarrena-Echeverria R. Prognostic value of lymph node micrometastases in patients with colorectal cancer in Dukes stages A and B (T1-4, N0, M0). Rev Esp Enferm Dig (Madrid) 2010; 102: 176-186.
5. Des Guetz G, Uzzan B, Nicolas P et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 2006; 94: 1823-1832.
6. Hurwith H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350335-2342.
7. Saltz L. Evaluation of Bevacizumab in the Adjuvant Treatment of Colon Cancer. Curr Colorectal Cancer Rep 2010; 6: 109-110.
8. Cong Wang, Shaoqiang Lin, Yanfang Nie et al. Mechanism of antitumor effect of a novel bFGF binding peptide on human colon cancer cells. Cancer Sci 2010; 101: 1212-1218.
9. Tassi E, Wellstein A. Tumor Angiogenesis: Initiation and targeting-therapeutic targeting of a FGF-binging protein, an angiogenic switch molecule and indicator of early stages of gastrointestinal adenocarcinomas. Cancer Res Treat 2006; 3889-197.
10. Li C, Shintani S, Terakado N et al. Microvessel density and expression of vascular endothelial growth factor, basic fibroblast growth factor, and platelet-derived growth factor in oral squamous cell carcinoma. Int J Oral Maxilofac Surg 2005; 34: 559-563.
11. Fujimoto K, Hosotani R, Wada M et al. Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur J Cancer 1998; 34: 1439-1447.
12. Takahashi Y, Bucana CD, Liu W et al. Platelet derived endothelial cell growth factor in human colon cancer angiogenesis: Role of infiltrating cells. J Natl Cancer Inst 1996; 88: 1146-1151.